MTVA supply chain intelligence for MetaVia Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
MetaVia Inc. (MTVA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DONG-A-ST | DONG-A-ST | 92% | In particular, we rely on Dong-A ST to provide services with respect to our development of vanoglipel (DA-1241) and DA-1726. |
| DONG-A-ST-CO-LTD | DONG-A-ST-CO-LTD | 92% | In addition, the Shared Services Agreement provides that Dong-A ST will manufacture all of our clinical requirements of vanoglipel and DA-1726 under the terms provided in the Shared Services Agreement. |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from AZN grap… |
| AZN | AstraZeneca PLC | 72% | ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or… |
| BMY | Bristol-Myers Squibb Company | 72% | ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from BMY graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered u… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares register… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or… |
| GALT | Galectin Therapeutics Inc. | 72% | Reciprocal relationship from GALT graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from GALT graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered… |
| GALT | Galectin Therapeutics Inc. | 72% | ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or… |
| GLMD | Galmed Pharmaceuticals Ltd. | 72% | Reciprocal relationship from GLMD graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from GLMD g… |
| GLMD | Galmed Pharmaceuticals Ltd. | 72% | ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market.… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or… |
| VKTX | Viking Therapeutics, Inc. | 72% | ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from VKTX g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | ur stock, Dong-A ST will be able to cause or prevent a change of control of us or a change in the composition of our Board and could preclude any unsolicited acquisition of us. The concentration of o… |
| DONG-A-HOLDINGS | DONG-A-HOLDINGS | 62% | ur stock, Dong-A ST will be able to cause or prevent a change of control of us or a change in the composition of our Board and could preclude any unsolicited acquisition of us. The concentration of o… |
| DONG-A-ST-CO-LTD | DONG-A-ST-CO-LTD | 62% | nts are expensed as the related goods are delivered or the services are performed. K. General and administrative expenses General and administrative expenses consist primarily of personnel-related co… |
| DONG-A-ST-DONG-A-HOLDINGS | DONG-A-ST-DONG-A-HOLDINGS | 62% | ur stock, Dong-A ST will be able to cause or prevent a change of control of us or a change in the composition of our Board and could preclude any unsolicited acquisition of us. The concentration of o… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MTVA-DEBT | Debt stack $194,000 | 90% | Market cache reports total debt of $194,000. |
| MTVA-DEBT-11127 | Warrants outstanding: 993204 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| MTVA-DEBT-11128 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MTVA-OWNER-TOWER-RESEARCH-CAPITAL-LLC-TRC | Tower Research Capital LLC (TRC) | 95% | 13F/ownership overlay lists Tower Research Capital LLC (TRC); shares held 244; value $344; as of 2025-12-31. |
| MTVA-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 1,860; ownership 0.04%; value $2,622; as of 2025-12-31. |
| MTVA-OWNER-CITADEL-ADVISORS-LLC | Citadel Advisors Llc | 95% | 13F/ownership overlay lists Citadel Advisors Llc; shares held 12,192; ownership 0.24%; value $17,190; as of 2025-12-31. |
| MTVA-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 20,088; ownership 0.39%; value $28,324; as of 2025-12-31. |
| MTVA-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 479; ownership 0.01%; value $675; as of 2025-12-31. |
| MTVA-OWNER-BROWN-BROTHERS-HARRIMAN-CO | Brown Brothers Harriman & Co | 95% | 13F/ownership overlay lists Brown Brothers Harriman & Co; shares held 2; value $2; as of 2025-12-31. |
| MTVA-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 1,300; ownership 0.03%; value $1,832; as of 2025-12-31. |
| MTVA-OWNER-JPMORGAN-CHASE-CO | JPMORGAN CHASE & CO | 95% | 13F/ownership overlay lists JPMORGAN CHASE & CO; shares held 22; value $31; as of 2025-12-31. |
| MTVA-OWNER-SBI-SECURITIES-CO-LTD | SBI Securities Co., Ltd. | 95% | 13F/ownership overlay lists SBI Securities Co., Ltd.; shares held 141; value $198; as of 2025-12-31. |
| MTVA-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 8; value $11; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| GALT | Galectin Therapeutics Inc. | 100.00 | 1 | ['supplier'] |
| VKTX | Viking Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| GLMD | Galmed Pharmaceuticals Ltd. | 100.00 | 1 | ['supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['supplier'] |
| IONS | Ionis Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 1 | ['supplier'] |
| EMMA | Emmaus Life Sciences, Inc. | 50.00 | 2 | |
| DEO | Diageo plc | 50.00 | 2 | |
| CEROW | CERO THERAPEUTICS HOLDINGS, INC. | 50.00 | 2 | |
| LGNZZ | LIGAND PHARMACEUTICALS INC | 50.00 | 2 | |
| CORT | Corcept Therapeutics Incorporated | 50.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 50.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 50.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 50.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 50.00 | 2 | |
| FULC | Fulcrum Therapeutics, Inc. | 50.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 50.00 | 2 |